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Anaphylactic reactions may occur unrelated to dose, but these are severe and acute. Radiation exposure may produce non-stochastic or deterministic effects that are dose-related (eg, skin erythema, infertility, cataract) but also stochastic or random effects such as cancer and genetic mutations. 4 The incidence of these stochastic effects increases with radiation dose but the severity does not. 5 Stochastic or random major side effects are not described in pharmacology independent of dose. The dose-response relationship is integral to modern pharmacology as well as regulatory guidance documents for characterizing drug safety and effectiveness. Without a dose effect, there is no causation. If there is no causation, the relationship we are observing must be an association.
To explore the potential paclitaxel dose argument, we must discuss the limitations of dose-effect assessment used in the meta-analysis. 1 We will then review patient level data analysis of the dose-mortality relationship. Finally, and most importantly, we will present new data on all-cause mortality of the 3 pivotal trials with 5-year follow-up that informed the United States Food and Drug Administration (FDA) in their March 15, 2019, statement on paclitaxel. 6 It is important to acknowledge that paclitaxel has been used in over 100-fold greater doses in oncology applications for many years without evidence of paclitaxel-related mortality or a dose effect. 7, 8 Oncology regimes typically involve weekly intravenous paclitaxel doses for 18 weeks. 9 By comparison, blood levels of paclitaxel are immeasurable beyond 1 week post-treatment in pharmacokinetic studies of almost all paclitaxel-eluting devices, 10 and tissue levels are not detected beyond 6 months.
While the summary level meta-analysis 1 used sound methodology, the dose-mortality calculations and underlying assumptions have been widely criticized. The authors used mean values for lesion length and reference vessel diameter taken over the entire study because only summary level data were available for assessment. However, the use of lesion length is imprecise because it is common practice to overlap multiple drug-coated balloons (DCBs) and include adjacent normal vessel wall to avoid geographic miss. Patient-level data, with precise measurement of actual device length and diameter, is the most accurate method of overcoming those shortcomings.
Moreover, the authors incorrectly assumed drug-eluting stents (DES) liberate paclitaxel over the entire lumen surface of the vessel. While the Zilver PTX DES (Cook Medical, Bloomington, IN, USA) has a paclitaxel density of 3 µg/mm 2 , only 14% of its abluminal surface is coated with drug, substantially less than the amount assumed by the authors. A comparison of the 3 devices with 5-year pivotal trial data demonstrates that Zilver PTX is the device with the lowest dose of paclitaxel. Using the company instruction for use for a 6×120-mm device as a point of reference, Zilver PTX contains 1.1 mg paclitaxel, the Lutonix DCB Finally, and perhaps most importantly, the exposure equation devised by the authors included time. This time variable corresponds to study follow-up time reported in the publication or presentation, not drug residence in the target tissue or systemic circulation. The time relationship posed by the authors assumes that the dose is stable and remains constant over time. There is no evidence in any preclinical or clinical study to suggest that this is true. The concept is fundamentally flawed, as the time parameter used in this way penalizes older studies with longer follow-up. Thus, studies at shorter follow-up will be biased toward the null and longer followup studies biased toward finding a stronger association between paclitaxel-coated devices and greater mortality.
Aggregate data meta-analysis has limitations, particularly in the determination of specific details required for a patient-dose analysis. Conventionally this would be performed as an intention-to-treat (ITT) analysis where subjects are analyzed within the group into which they were randomized, regardless of their eventual treatment. This is done to preserve the randomization effect, which is the best method of eliminating confounding and is accepted as the method of choice when investigating efficacy. However, to investigate mortality due to drug exposure it is fundamental that subjects be analyzed according to their actual exposure. It is not the efficacy of two treatments being compared but a drug toxicity analysis that must be based on actual, rather than theoretical exposure.
The complex, double randomization design of the Cook Zilver PTX pivotal trial allowed for a significant (40%) crossover in the angioplasty arm in the first 12 months. 11 In contrast to the ITT analysis, an as-treated analysis showed no difference in 5-year mortality between patients exposed to paclitaxel and those not. 11 Similarly, an independently (Baim Institute for Clinical Research, Boston, MA, USA) analyzed patient-level meta-analysis of trials using the Medtronic IN.PACT Admiral DCB divided patients into 3 terciles of paclitaxel dose and showed no dose-mortality relationship. 12 Indeed, the highest dose tercile had the lowest mortality at 5 years, providing rigorously adjudicated, patient-level, clinical trial evidence to counter the dosemortality relationship theory. Several other patient-level analyses of paclitaxel devices [13] [14] [15] have also failed to show a dose-mortality relationship, underscoring the consistency in findings when actual exposure is the focus of the analysis.
The FDA released an updated letter to health care providers on March 15, 2019. 6 It was based on a preliminary analysis of the long-term data from the 3 pivotal premarket trials evaluating paclitaxel-coated products for the treatment of peripheral artery occlusive disease: the Medtronic IN.PACT SFA I and II, 16, 17 Cook Zilver PTX, 18 and the BD/ Bard LEVANT 2 19 randomized controlled trials (RCTs). The FDA noted a significant increase in the crude risk of death for paclitaxel-coated devices vs control devices. However, it was also noted that each of the trials used "allcause" mortality calculation methods that differed significantly and had the potential to influence the way those results were presented and interpreted.
Medtronic used the "proportion method" for calculating 5-year mortality:
Totalnumber of patients who died Number of patientsfollowed to5 year rs , which produced a 15.8% (29/184) mortality for the 220 patients enrolled in the trial. This method excludes patients lost to follow-up, with the rationale that it is unknown whether these patients are alive or dead. Cook analyzed the Zilver PTX trial using a calculation method that divided number of deaths by those initially randomized to each treatment arm (the conventional ITT method: 16.9%, 41/242). BD/Bard chose to censor the deaths in the LEVANT 2 trial, using an independent physician panel to remove deaths "that could not reasonably be attributed to paclitaxel" (eg, known pre-existing conditions). They also used all patients initially enrolled as the denominator (5.7%, 18/316).
To facilitate a direct mortality comparison between the 3 trials, we asked each of the companies to provide 5-year mortality using the same proportional methods as used by Medtronic (summarized in Table 1 ). This consistent methodology allowed for a direct comparison of product dose to test the dose-response theory proposed by the meta-analysis. 1 The highest 5-year mortality was found to be associated with the lowest paclitaxel dose device (Zilver PTX), while the lowest mortality was associated with the highest dose device (IN.PACT). It is our view that this directly refutes the causal relationship theory between paclitaxel dose and all-cause mortality.
It is important to note that there is no significant difference in the 5-year mortality calculated using proportional methodology between paclitaxel-coated balloons compared to controls in the Medtronic IN.PACT and BD/Bard LEVANT 2 trials (Table 1) ; only the Zilver PTX DES displayed a significant difference (p=0.008) between the arms. When the Zilver PTX RCT 5-year data are reanalyzed by ITT, the mortality of the paclitaxel-eluting stent remains the highest (22.7%) of the 3 paclitaxel devices, but the mortality difference compared to the control arm (18.5%) loses its significance (p=0.45).
The proportional methodology calculates mortality while methods such as Kaplan-Meier calculate survival. A limitation of the proportional method is that the denominator may change as patients previously lost to follow-up are contacted. A survival method such as Kaplan-Meier may be superior because it is designed to accommodate random events such as death in patients lost to follow-up. While Kaplan-Meier survival plots are not available for all 3 pivotal studies with 5-year follow-up, as more patients previously lost to follow-up are successfully contacted, proportional and survival methodologies will produce complimentary findings. A significant flaw of the meta-analysis 1 is the high number of patients lost to follow-up at 5 years when analyzing a low frequency endpoint such as mortality. We believe it is likely, even with more complete patient follow-up, that the lack of correlation between paclitaxel dose and mortality will persist.
Given that the causation theory behind paclitaxel and mortality now appears unlikely, a plausible explanation for the association between paclitaxel exposure and late mortality is required. An in-depth discussion is beyond the scope of this article, but factors that may contribute to this association are given in Table 2 . Ascertainment, performance, and detection bias are likely to be important. These may explain the observation that higher mortality is frequently demonstrated in the experimental arm than in the control arm of vascular device trials even in non-paclitaxel studies. Crossover refers to patients exposed to paclitaxel when undergoing reintervention to the target lesion. However, it is likely that many patients were also exposed to paclitaxel when non-target arterial lesions were treated in the ipsilateral or contralateral leg. Unfortunately, none of the trials included in the meta-analysis 1 captured this data. Perhaps the most important lesson from this paclitaxel debate may be the need to reconsider and significantly modify the way vascular device trials are performed in the future. We believe there should be an additional emphasis placed on adherence to guidelines-based medical therapy of all enrolled patients as well as safety endpoints such as mortality. Greater effort must be made to reduce subjects lost to follow-up and properly classify the mortality status of those subjects who withdraw.
It is only with well-conducted safety evaluations that we will completely clarify this issue regarding paclitaxel. Given the known and undisputed benefits of paclitaxel coating on stents and angioplasty balloons, we owe it to our patients to pursue that truth before we restrict these devices from use. 
